T 1821/18 (RGM A binding proteins for treatment of retinal nerve fiber layer degeneration/ABBVIE) of 11.11.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T182118.20211111
- Date of decision
- 11 November 2021
- Case number
- T 1821/18
- Online on
- 20 July 2022
- Petition for review of
- -
- Application number
- 10794938.0
- IPC class
- A61K 39/395C07K 16/22
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
- Applicant name
- AbbVie Deutschland GmbH & Co KG
- Opponent name
- Mitsubishi Tanabe Pharma Corporation
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(a)European Patent Convention Art 100(b)European Patent Convention Art 54(2)European Patent Convention Art 56Rules of procedure of the Boards of Appeal Art 12(4)
- Keywords
- Grounds for opposition - insufficiency of disclosure (no)
Late-filed facts - request could have been filed in first instance proceedings (yes)
Novelty - second (or further) medical use
Inventive step - reasonable expectation of success (no) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.